Finanzen von Oragenics Inc (OGEN)OGENOragenics Inc

Evaluating the bottom line, Oragenics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -1307.06%, provide a clear picture of how effectively OGEN converts its operational activities into shareholder value.

In the context of the broader market, OGEN competes directly with industry leaders such as ONCO and SHPH. With a market capitalization of $2.37M, it holds a significant position in the sector. When comparing efficiency, OGEN's gross margin of N/A stands against ONCO's 25.13% and SHPH's N/A. Such benchmarking helps identify whether Oragenics Inc is trading at a premium or discount relative to its financial performance.

Oragenics has reported consistent net losses, with the latest quarterly net income at -2,528,707 USD. The company has a current ratio of 3.01, indicating it can cover its short-term liabilities, but the overall financial health remains concerning due to ongoing losses.